288 related articles for article (PubMed ID: 27379214)
1. Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection.
Boianelli A; Sharma-Chawla N; Bruder D; Hernandez-Vargas EA
Front Cell Infect Microbiol; 2016; 6():60. PubMed ID: 27379214
[TBL] [Abstract][Full Text] [Related]
2. Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
Onishi M; Kitano M; Taniguchi K; Homma T; Kobayashi M; Yoshinaga T; Naito A; Sato A
Antiviral Res; 2015 May; 117():52-9. PubMed ID: 25752738
[TBL] [Abstract][Full Text] [Related]
3. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
[TBL] [Abstract][Full Text] [Related]
4. Memory Th17 cell-mediated protection against lethal secondary pneumococcal pneumonia following influenza infection.
Li Y; Yang Y; Chen D; Wang Y; Zhang X; Li W; Chen S; Wong SM; Shen M; Akerley BJ; Shen H
mBio; 2023 Aug; 14(4):e0051923. PubMed ID: 37222516
[No Abstract] [Full Text] [Related]
5. PK/PD-based adaptive tailoring of oseltamivir doses to treat within-host influenza viral infections.
Montaseri G; Boianelli A; Hernandez-Vargas EA; Meyer-Hermann M
Prog Biophys Mol Biol; 2018 Nov; 139():31-42. PubMed ID: 30031022
[TBL] [Abstract][Full Text] [Related]
6. Viral Interference During Influenza A-SARS-CoV-2 Coinfection of the Human Airway Epithelium and Reversal by Oseltamivir.
Cheemarla NR; Watkins TA; Mihaylova VT; Foxman EF
J Infect Dis; 2024 May; 229(5):1430-1434. PubMed ID: 37722683
[TBL] [Abstract][Full Text] [Related]
7. Neuraminidase Inhibitors in Influenza Treatment and Prevention⁻Is It Time to Call It a Day?
Parra-Rojas C; Nguyen VK; Hernandez-Mejia G; Hernandez-Vargas EA
Viruses; 2018 Aug; 10(9):. PubMed ID: 30149615
[TBL] [Abstract][Full Text] [Related]
8. Mathematical modeling of postcoinfection with influenza A virus and
Cheng YH; You SH; Lin YJ; Chen SC; Chen WY; Chou WC; Hsieh NH; Liao CM
Int J Chron Obstruct Pulmon Dis; 2017; 12():1973-1988. PubMed ID: 28740377
[TBL] [Abstract][Full Text] [Related]
9. Frequency and effects of bacterial infection in children with influenza under oseltamivir treatment.
Ninomiya K; Madenokouji N; Hajikano M; Kawabata K; Matsuoka K; Fukunaga Y
J Nippon Med Sch; 2006 Jun; 73(3):122-8. PubMed ID: 16790978
[TBL] [Abstract][Full Text] [Related]
10. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza.
McCullers JA
J Infect Dis; 2004 Aug; 190(3):519-26. PubMed ID: 15243927
[TBL] [Abstract][Full Text] [Related]
11. Influenza A Virus Infection Predisposes Hosts to Secondary Infection with Different Streptococcus pneumoniae Serotypes with Similar Outcome but Serotype-Specific Manifestation.
Sharma-Chawla N; Sender V; Kershaw O; Gruber AD; Volckmar J; Henriques-Normark B; Stegemann-Koniszewski S; Bruder D
Infect Immun; 2016 Dec; 84(12):3445-3457. PubMed ID: 27647871
[TBL] [Abstract][Full Text] [Related]
12. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
[TBL] [Abstract][Full Text] [Related]
13. [Neuraminidase inhibitors and risk of H5N1 influenza].
Gras-Masse H; Willand N
Ann Pharm Fr; 2007 Jan; 65(1):50-7. PubMed ID: 17299351
[TBL] [Abstract][Full Text] [Related]
14. Oseltamivir for treatment and prophylaxis of influenza infection.
Schirmer P; Holodniy M
Expert Opin Drug Saf; 2009 May; 8(3):357-71. PubMed ID: 19355841
[TBL] [Abstract][Full Text] [Related]
15. Towards a personalised approach to managing influenza infections in infants and children - food for thought and a note on oseltamivir.
Rath B; Tief F; Karsch K; Muehlhans S; Obermeier P; Adamou E; Chen X; Seeber L; Peiser C; Hoppe C; von Kleist M; Conrad T; Schweiger B
Infect Disord Drug Targets; 2013 Feb; 13(1):25-33. PubMed ID: 23675924
[TBL] [Abstract][Full Text] [Related]
16. Antiviral resistance and the control of pandemic influenza.
Lipsitch M; Cohen T; Murray M; Levin BR
PLoS Med; 2007 Jan; 4(1):e15. PubMed ID: 17253900
[TBL] [Abstract][Full Text] [Related]
17. The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice.
Tanaka A; Nakamura S; Seki M; Iwanaga N; Kajihara T; Kitano M; Homma T; Kurihara S; Imamura Y; Miyazaki T; Izumikawa K; Kakeya H; Yanagihara K; Kohno S
Antivir Ther; 2015; 20(1):11-9. PubMed ID: 24517996
[TBL] [Abstract][Full Text] [Related]
18. Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic.
Dixit R; Khandaker G; Ilgoutz S; Rashid H; Booy R
Infect Disord Drug Targets; 2013 Feb; 13(1):34-45. PubMed ID: 23675925
[TBL] [Abstract][Full Text] [Related]
19. A Murine Model for Enhancement of Streptococcus pneumoniae Pathogenicity upon Viral Infection and Advanced Age.
Joma BH; Siwapornchai N; Vanguri VK; Shrestha A; Roggensack SE; Davidson BA; Tai AK; Hakansson AP; Meydani SN; Leong JM; Bou Ghanem EN
Infect Immun; 2021 Jul; 89(8):e0047120. PubMed ID: 34031128
[TBL] [Abstract][Full Text] [Related]
20. The inhibitory effect of sodium baicalin on oseltamivir-resistant influenza A virus via reduction of neuraminidase activity.
Jin J; Chen Y; Wang D; Ma L; Guo M; Zhou C; Dou J
Arch Pharm Res; 2018 Jun; 41(6):664-676. PubMed ID: 29572682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
